Skip to main content

From the helm: Immutep’s (ASX:IMM) Executive Director & CEO Marc Voigt

Sophia Mavridis
April 6, 2022

In this instalment of our From the helm series, Bell Direct’s Sophia Mavridis speaks to Immutep’s (ASX:IMM) Executive Director and CEO, Marc Voigt.

Global biotechnology company, Immutep is a leading developer of autoimmune and cancer immunotherapy treatments. The business has been gaining a lot of attention lately as its lead product is in its late-stage clinical trials for metastatic breast cancer.

In this video Marc discusses:

  • (0:40) What IMM does and its key strength in the market
  • (1:27) The impact of the FDA’s recent feedback on its lead product
  • (2:53) IMM’s collaborations with big pharma names like Pfizer & Merck
  • (4:03) When to expect data from its current clinical trials
  • (5:10) What’s coming up for IMM

Note: This interview was filmed on 22 March 2022.

Weekly Wrap 12 August

Sophia Mavridis
August 12, 2022

Morning Bell 11 August

Paulina Peters
August 11, 2022

Morning Bell 10 August

Sophia Mavridis
August 10, 2022

Morning Bell 9 August

Paulina Peters
August 9, 2022

Morning Bell 8 August

Sophia Mavridis
August 8, 2022

Weekly Wrap 5 August

Sophia Mavridis
August 5, 2022

Morning Bell 4 August

Paulina Peters
August 4, 2022

Morning Bell 3 August

Sophia Mavridis
August 3, 2022

Morning Bell 2 August

Paulina Peters
August 2, 2022

Morning Bell 1 August

Sophia Mavridis
August 1, 2022

Weekly Wrap 29 July

Sophia Mavridis
July 29, 2022